Skip to content
★ Sign in to follow
MG

Michael Gibertini

CEO
Syneos Health, Inc.
Total declarations
37
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (19 ops.)
€11.5M

Latest filing published 02 Aug 2017 for Syneos Health, Inc..

Insider track record

Disclosed buys
0
Disclosed sells
19
Signal history

Michael Gibertini: trading record in brief

This profile gathers the share dealings of Michael Gibertini in Syneos Health, Inc. We count 37 filings; the first trade dates from 7 May 2015 and the latest from 1 August 2017.

Every open-market trade on record is a sale: 19 sales worth €11.5M. Outside the open market, there are 7 share grants and 11 option exercises.

The latest filing, published on 2 August 2017, reports an option exercise in Syneos Health, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Michael Gibertini

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations37 total
  • ◇
    ExecutivesSyneos Health, Inc.
    0SEC
    10,567 shares0Class A Common StockSEC:0001630998-17-000004:0
  • ◇
    ExecutivesSyneos Health, Inc.
    0SEC
    11,000 shares0Class A Common StockSEC:0001630998-17-000004:1
  • ◆
    Chief Operating OfficerExecutivesSyneos Health, Inc.
    33,696 USD11SEC
    576 shares@ US$58.500.3% of flowClass A Common StockSEC:0001630998-17-000003:0
  • ◆
    Chief Operating OfficerExecutivesSyneos Health, Inc.
    0SEC
    10,567 shares0Class A Common StockSEC:0001630998-17-000002:0
  • ◆
    Chief Operating OfficerExecutivesSyneos Health, Inc.
    42,310 USD11SEC
    837 shares@ US$50.550.4% of flowClass A Common StockSEC:0001630998-17-000001:0
  • ◆
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    0SEC
    29,110 shares0Class A Common StockSEC:0001630998-16-000013:0
  • ◆
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    33,669 USD22SEC
    883 shares@ US$38.130.3% of flowClass A Common StockSEC:0001630998-16-000012:0
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    1M USD23SEC
    153,716 shares@ US$8.4510.2% of flowClass A Common StockSEC:0001630998-16-000011:0
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    6M USD39SEC
    144,682 shares@ US$43.0548.7% of flowClass A Common StockSEC:0001630998-16-000011:1
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    395,960 USD34SEC
    9,034 shares@ US$43.833.1% of flowClass A Common StockSEC:0001630998-16-000011:2
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    154,618 USD22SEC
    14,628 shares@ US$10.571.2% of flowClass A Common StockSEC:0001630998-16-000011:3
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    593,906 USD34SEC
    13,751 shares@ US$43.194.6% of flowClass A Common StockSEC:0001630998-16-000011:4
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    38,430 USD34SEC
    877 shares@ US$43.820.3% of flowClass A Common StockSEC:0001630998-16-000011:5
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    285,097 USD22SEC
    17,752 shares@ US$16.062.2% of flowClass A Common StockSEC:0001630998-16-000011:6
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    716,869 USD35SEC
    16,652 shares@ US$43.055.6% of flowClass A Common StockSEC:0001630998-16-000011:7
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    48,136 USD34SEC
    1,100 shares@ US$43.760.4% of flowClass A Common StockSEC:0001630998-16-000011:8
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    1M USD35SEC
    26,394 shares@ US$43.058.9% of flowClass A Common StockSEC:0001630998-16-000011:9
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    64,708 USD34SEC
    1,476 shares@ US$43.840.5% of flowClass A Common StockSEC:0001630998-16-000011:10
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    76,050 USD22SEC
    9,000 shares@ US$8.450.6% of flowClass A Common StockSEC:0001630998-16-000010:0
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    367,020 USD22SEC
    9,000 shares@ US$40.782.9% of flowClass A Common StockSEC:0001630998-16-000010:1
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    76,050 USD22SEC
    9,000 shares@ US$8.450.6% of flowClass A Common StockSEC:0001630998-16-000009:0
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    358,650 USD37SEC
    9,000 shares@ US$39.852.9% of flowClass A Common StockSEC:0001630998-16-000009:1
  • ◇
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    0SEC
    9,000 sharesClass A Common StockSEC:0001630998-16-000008:0
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    323,592 USD38SEC
    8,000 shares@ US$40.44941.2% of flowClass A Common StockSEC:0001630998-16-000008:1
  • ▼
    President Clinical DevelopmentExecutivesSyneos Health, Inc.
    41,560 USD35SEC
    1,000 shares@ US$41.565.3% of flowClass A Common StockSEC:0001630998-16-000008:2

25 of 37 declarations